Stone House Investment Management’s Viking Therapeutics VKTX Stock Holding History

Stone House Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26K	Hold	800	–	–	﹤0.01%	254
2025 Q4	$28.1K	Hold	800	–	–	﹤0.01%	220
2025 Q3	$21K	Hold	800	–	–	﹤0.01%	222
2025 Q2	$21.2K	Buy	800 +500	+167%	+$13.2K	﹤0.01%	210
2025 Q1	$7.25K	Buy	+300	New	+$9.48K	﹤0.01%	279
2024 Q4	–	Sell	-500	Closed	-$31.7K	–	345
2024 Q3	$31.7K	Buy	500 +200	+67%	+$11.7K	0.01%	146
2024 Q2	$15.9K	Hold	300	–	–	﹤0.01%	195
2024 Q1	$24.6K	Buy	300 +50	+20%	+$2.23K	0.01%	181
2023 Q4	$4.65K	Hold	250	–	–	﹤0.01%	219
2023 Q3	$2.77K	Hold	250	–	–	﹤0.01%	240
2023 Q2	$4.05K	Buy	+250	New	+$5.24K	﹤0.01%	217

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Stone House Investment Management's VKTX Position: Q1 2026 in Review

Stone House Investment Management held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 800 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #254.

Stone House Investment Management first reported a position in VKTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $31.7K in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Stone House Investment Management held 800 shares of Viking Therapeutics worth $26K as of Q1 2026.
Stone House Investment Management left its Viking Therapeutics share count unchanged in Q1 2026.
Viking Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #254 holding.
Stone House Investment Management first reported a position in Viking Therapeutics in Q2 2023 and has held it in 11 quarters since.
Stone House Investment Management's Viking Therapeutics position peaked at $31.7K in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.